EGFR and non-small cell lung carcinoma: Amivantamab-vmjm (Rybrevant), targeting EGFR and the mesenchymal-epithelial transition factor (c-Met) mutant signaling pathway, was first approved for the treatment of NSCLC on 21 May 2021 in the USA [149, 150].